|
1
|
Weickert MO and Pfeiffer AF: Signalling
mechanisms linking hepatic glucose and lipid metabolism.
Diabetologia. 49:1732–1741. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Samuel VT and Shulman GI: Mechanisms for
insulin resistance: Common threads and missing links. Cell.
148:852–871. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Solinas G, Naugler W, Galimi F, Lee MS and
Karin M: Saturated fatty acids inhibit induction of insulin gene
transcription by JNK-mediated phosphorylation of insulin-receptor
substrates. Proc Natl Acad Sci USA. 103:16454–16459. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirosumi J, Tuncman G, Chang L, Görgün CZ,
Uysal KT, Maeda K, Karin M and Hotamisligil GS: A central role for
JNK in obesity and insulin resistance. Nature. 420:333–336. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galbo T, Olsen GS, Quistorff B and
Nishimura E: Free fatty acid-induced PP2A hyperactivity selectively
impairs hepatic insulin action on glucose metabolism. PLoS One.
6:e274242011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bahlmann FH and Fliser D: Erythropoietin
and renoprotection. Curr Opin Nephrol Hypertens. 18:15–20. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mitsuma W, Ito M, Kodama M, Fuse K,
Okamura K, Minagawa S, Kato K, Hanawa H, Toba K, Nakazawa M and
Aizawa Y: Cardioprotective effects of recombinant human
erythropoietin in rats with experimental autoimmune myocarditis.
Biochem Biophys Res Commun. 344:987–994. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Villa P, Bigini P, Mennini T, Agnello D,
Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman
TR, et al: Erythropoietin selectively attenuates cytokine
production and inflammation in cerebral ischemia by targeting
neuronal apoptosis. J Exp Med. 198:971–975. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rasic-Milutinovic Z, Perunicic-Pekovic G,
Cavala A, Gluvic Z, Bokan L and Stankovic S: The effect of
recombinant human erythropoietin treatment on insulin resistance
and inflammatory markers in non-diabetic patients on maintenance
hemodialysis. Hippokratia. 12:157–161. 2008.PubMed/NCBI
|
|
10
|
Meng R, Zhu D, Bi Y, Yang D and Wang Y:
Erythropoietin inhibits gluconeogenesis and inflammation in the
liver and improves glucose intolerance in high-fat diet-fed mice.
PLoS One. 8:e535572013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao D, Nong S, Huang X, Lu Y, Zhao H, Lin
Y, Man Y, Wang S, Yang J and Li J: The effects of palmitate on
hepatic insulin resistance are mediated by NADPH Oxidase 3-derived
reactive oxygen species through JNK and p38MAPK pathways. J Biol
Chem. 285:29965–29973. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Copps KD and White MF: Regulation of
insulin sensitivity by serine/threonine phosphorylation of insulin
receptor substrate proteins IRS1 and IRS2. Diabetologia.
55:2565–2582. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(−Delta Delta C(T) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Taniguchi CM, Ueki K and Kahn R:
Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of
metabolism. J Clin Invest. 115:718–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Piro S, Maniscalchi ET, Monello A, Pandini
G, Mascali LG, Rabuazzo AM and Purrello F: Palmitate affects
insulin receptor phosphorylation and intracellular insulin signal
in a pancreatic alpha-cell line. Endocrinology. 151:4197–4206.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arcasoy MO: The non-haematopoietic
biological effects of erythropoietin. Br J Haemato. 141:14–31.
2008. View Article : Google Scholar
|
|
17
|
Allegra V, Mengozzi G, Martimbianco L and
Vasile A: Early and late effects of erythropoietin on glucose
metabolism in maintenance hemodialysis patients. Am J Nephrol.
16:304–308. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khedr E, El-Sharkawy M, Abdulwahab S,
Eldin EN, Ali M, Youssif A and Ahmed B: Effect of recombinant human
erythropoietin on insulin resistance in hemodialysis patients.
Hemodial Int. 13:340–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tuzcu A, Bahceci M, Yilmaz E, Bahceci S
and Tuzcu S: The comparison of insulin sensitivity in non-diabetic
hemodialysis patients treated with and without recombinant human
erythropoietin. Horm Metab Res. 36:716–720. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Teng R, Gavrilova O, Suzuki N, Chanturiya
T, Schimel D, Hugendubler L, Mammen S, Yver DR, Cushman SW, Mueller
E, et al: Disrupted erythropoietin signalling promotes obesity and
alters hypothalamus proopiomelanocortin production. Nat Commun.
2:5202011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hojman P, Brolin C, Gissel H, Brandt C,
Zerahn B, Pedersen BK and Gehl J: Erythropoietin over-expression
protects against diet-induced obesity in mice through increased fat
oxidation in muscles. PLoS One. 4:e58942009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan Y, Shu JL, Gu HF, Zhou DC, Liu XL,
Qiao QY, Fu SK, Gao FH and Jin HM: Erythropoietin improves insulin
resistance via the regulation of its receptor-mediated signaling
pathway in 3T3L1 adipocytes. Mol Cell Endocrinol. 367:116–123.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang L, Teng R, Di L, Rogers H, Wu H, Kopp
JB and Noguchi CT: PPARα and Sirt1 mediate erythropoietin action in
increasing metabolic activity and browning of white adipocytes to
protect against obesity and metabolic disorders. Diabetes.
62:4122–4131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haus JM, Solomon TP, Marchetti CM, Edmison
JM, González F and Kirwan JP: Free fatty acid-induced hepatic
insulin resistance is attenuated following lifestyle intervention
in obese individuals with impaired glucose tolerance. J Clin
Endocrinol Metab. 95:323–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hotamisligil GS: Inflammation and
metabolic disorders. Nature. 444:860–867. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Solinas G and Karin M: JNK1 and IKKbeta:
Molecular links between obesity and metabolic dysfunction. FASEB J.
24:2596–2611. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanti JF and Jager J: Cellular mechanisms
of insulin resistance: Role of stress-regulated serine kinases and
insulin receptor substrates (IRS) serine phosphorylation. Curr Opin
Pharmacol. 9:753–762. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taniguchi CM, Kondo T, Sajan M, Luo J,
Bronson R, Asano T, Farese R, Cantley LC and Kahn CR: Divergent
regulation of hepatic glucose and lipid metabolism by
phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab.
3:343–353. 2006. View Article : Google Scholar : PubMed/NCBI
|
